170 related articles for article (PubMed ID: 34702300)
21. Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase.
Miller AT; Berg LJ
J Immunol; 2002 Mar; 168(5):2163-72. PubMed ID: 11859102
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of IL-2 inducible T-cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection.
He F; Yao H; Xiao Z; Han J; Zou J; Liu Z
Mol Immunol; 2014 May; 59(1):30-8. PubMed ID: 24462896
[TBL] [Abstract][Full Text] [Related]
23. Blockade of interleukin-2-inducible T-cell kinase signaling attenuates acute lung injury in mice through adjustment of pulmonary Th17/Treg immune responses and reduction of oxidative stress.
Nadeem A; Al-Harbi NO; Ahmad SF; Al-Harbi MM; Alhamed AS; Alfardan AS; Assiri MA; Ibrahim KE; Albassam H
Int Immunopharmacol; 2020 Jun; 83():106369. PubMed ID: 32163900
[TBL] [Abstract][Full Text] [Related]
24. IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
Carson CC; Moschos SJ; Edmiston SN; Darr DB; Nikolaishvili-Feinberg N; Groben PA; Zhou X; Kuan PF; Pandey S; Chan KT; Jordan JL; Hao H; Frank JS; Hopkinson DA; Gibbs DC; Alldredge VD; Parrish E; Hanna SC; Berkowitz P; Rubenstein DS; Miller CR; Bear JE; Ollila DW; Sharpless NE; Conway K; Thomas NE
Clin Cancer Res; 2015 May; 21(9):2167-76. PubMed ID: 25934889
[TBL] [Abstract][Full Text] [Related]
25. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma.
Pan B; Yang M; Wei X; Li W; Wang K; Yang M; Lu D; Wang R; Cen B; Xu X
Aging (Albany NY); 2021 Jul; 13(14):18620-18644. PubMed ID: 34282055
[TBL] [Abstract][Full Text] [Related]
27. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional signatures of Itk-deficient CD3+, CD4+ and CD8+ T-cells.
Blomberg KE; Boucheron N; Lindvall JM; Yu L; Raberger J; Berglöf A; Ellmeier W; Smith CE
BMC Genomics; 2009 May; 10():233. PubMed ID: 19450280
[TBL] [Abstract][Full Text] [Related]
29. Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.
Yue H; Wang J; Chen R; Hou X; Li J; Lu X
BMC Cancer; 2019 Dec; 19(1):1266. PubMed ID: 31888563
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A.
Brazin KN; Mallis RJ; Fulton DB; Andreotti AH
Proc Natl Acad Sci U S A; 2002 Feb; 99(4):1899-904. PubMed ID: 11830645
[TBL] [Abstract][Full Text] [Related]
31. TCR/ITK Signaling in Type 1 Regulatory T cells.
McGee MC; August A; Huang W
Adv Exp Med Biol; 2021; 1278():115-124. PubMed ID: 33523446
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Alqahtani F; As Sobeai HM; Alotaibi MR
Biochimie; 2020 Dec; 179():146-156. PubMed ID: 33007409
[TBL] [Abstract][Full Text] [Related]
33. Advances in the design of ITK inhibitors.
Charrier JD; Knegtel RM
Expert Opin Drug Discov; 2013 Apr; 8(4):369-81. PubMed ID: 23387379
[TBL] [Abstract][Full Text] [Related]
34. Identification of two molecular subtypes of dysregulated immune lncRNAs in ovarian cancer.
Liu X; Gao J; Wang J; Chu J; You J; Jin Z
Exp Biol Med (Maywood); 2021 Mar; 246(5):547-559. PubMed ID: 33203236
[TBL] [Abstract][Full Text] [Related]
35. IL-2-inducible T cell kinase tunes T regulatory cell development and is required for suppressive function.
Huang W; Jeong AR; Kannan AK; Huang L; August A
J Immunol; 2014 Sep; 193(5):2267-72. PubMed ID: 25063868
[TBL] [Abstract][Full Text] [Related]
36. TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.
Hussain A; Yu L; Faryal R; Mohammad DK; Mohamed AJ; Smith CI
FEBS J; 2011 Jun; 278(12):2001-10. PubMed ID: 21518255
[TBL] [Abstract][Full Text] [Related]
37. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.
Guo W; Liu R; Ono Y; Ma AH; Martinez A; Sanchez E; Wang Y; Huang W; Mazloom A; Li J; Ning J; Maverakis E; Lam KS; Kung HJ
Mol Pharmacol; 2012 Nov; 82(5):938-47. PubMed ID: 22899868
[TBL] [Abstract][Full Text] [Related]
38. Role of ITK signaling in acute kidney injury in mice: Amelioration of acute kidney injury associated clinical parameters and attenuation of inflammatory transcription factor signaling in CD4+ T cells by ITK inhibition.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Sarawi W; Attia SM; Alasmari AF; Alqarni SA; Alfradan AS; Bakheet SA; Al-Harbi MM
Int Immunopharmacol; 2021 Oct; 99():108028. PubMed ID: 34365077
[TBL] [Abstract][Full Text] [Related]
39. Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.
Lechner KS; Neurath MF; Weigmann B
J Mol Med (Berl); 2020 Oct; 98(10):1385-1395. PubMed ID: 32808093
[TBL] [Abstract][Full Text] [Related]
40. Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases.
Joseph RE; Kleino I; Wales TE; Xie Q; Fulton DB; Engen JR; Berg LJ; Andreotti AH
Sci Signal; 2013 Aug; 6(290):ra76. PubMed ID: 23982207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
